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CardiomyocytesInterleukin-6 mediates host defense and cell survival mainly through the activation of the transcription factor
STAT3 via the glycoprotein gp130, a shared signal-transducing receptor for several IL-6-type cytokines. We
have reported that the cardiotrophic parasite Trypanosoma cruzi protects murine cardiomyocytes from apo-
ptosis. In agreement, an intense induction of the anti-apoptotic factor Bcl-2 is found in cardiac ﬁbers during
the acute phase of infection, establishing a higher threshold against apoptosis. We report here that inactive
cruzipain, the main cysteine protease secreted by the parasite, speciﬁcally triggered TLR2 and the subsequent
release of IL-6, which acted as an essential anti-apoptotic factor for cardiomyocyte cultures. Although compa-
rable IL-6 levels were found under active cruzipain stimulation, starved cardiac cell monolayers could not be
rescued from apoptosis. Moreover, cardiomyocytes treated with active cruzipain completely abrogated the
STAT3 phosphorylation and nuclear translocation induced by recombinant IL-6. This inhibition was also ob-
served on splenocytes, but it was reverted when the enzyme was complexed with chagasin, a parasite cyste-
ine protease inhibitor. Furthermore, the inhibition of IL-6-induced p-STAT3 was evidenced in spleen cells
stimulated with pre-activated supernatants derived from trypomastigotes. To account for these observations,
we found that cruzipain enzymatically cleaved recombinant gp130 ectodomain, and induced the release of
membrane-distal N-terminal domain of this receptor on human peripheral blood mononuclear cells. These
results demonstrate, for the ﬁrst time, that the parasite may modify the IL-6-induced response through the
modulation of its cysteine protease activity, suggesting that speciﬁc inhibitors may help to improve the im-
mune cell activation and cardioprotective effects.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Myocarditis caused by infection with the intracellular protozoan
Trypanosoma cruzi still remains as the major infectious heart disease
worldwide. After infection, the parasite invades and multiplies in the
myocardium, leading to an acute myocarditis that kills around 5% of
non-treated infected individuals. However, this acute episode in
most cases self-resolves in about two months. During the subsequentminant-negative TLR2; GMFI,
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rights reserved.chronic phase, parasitemia is reduced to virtually undetectable levels
and the anti-parasite immune response recedes. Nonetheless, low
levels of T. cruzi DNA can still be detected in the heart despite the ab-
sence of prominent tissue parasitism, illustrating that long term para-
site persistence occurs in the presence of an intact immune system. In
addition, cardiomyocytes are terminally differentiated non-dividing
cells with minimal renewal capability, and it is therefore clear that
the loss of cardiomyocytes due to parasite infection cannot occur in
a timely manner and is detrimental to cardiac function. Consequently,
the strategies evolved by the host in order to protect cardiomyocytes
against initial or persistent parasite infection are critical for most of
the infected individuals.
Innate immunity provides the ﬁrst line of defense by detecting the
infectious agent through pattern recognition receptors, including toll-
like receptors (TLRs) [1,2]. Activation of TLRs on cardiac myocytes
leads to a Nuclear Factor-κB (NF-κB)-mediated cardiomyocyte in-
ﬂammatory response through cytokine release. Cumulative evidence
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axis in the biology of cellular survival, particularly in cardiac cells
[3,4]. Recently, we reported that TLR2-dependent signaling induces
IL-6 production, which acts as an essential anti-apoptotic factor and
plays a crucial role in murine cardiomyocyte protection during
T. cruzi infection [5].
The cytokine IL-6 belongs to a cytokine family that shares the
transmembrane glycoprotein gp130 as a common signal-transducing
receptor in responsive cells. The N-terminal extracellular region of
gp130 is formed by the immunoglobulin-like domain (D1), followed
by the cytokine-binding domains (D2–D3) and three membrane-
proximal ﬁbronectin type-III ones (D4, D5, and D6). The gp130 togeth-
er with the IL-6 receptor subunit-alpha (IL-6Rα) composes the func-
tional IL-6 receptor. When IL-6 binds to the alpha subunit, the binary
complex (IL-6–IL-6Rα) becomes competent to engage gp130 recep-
tor, and then the trimolecular complex (IL-6Rα–IL-6–gp130) dimer-
izes via the gp130 D1 domain [6]. The Janus tyrosine kinases that are
constitutively associated with gp130 become activated, resulting in
tyrosine phosphorylation of the transcription factor STAT3, which mi-
grates to the nucleuswhere it induces IL-6 target genes involved in de-
fense, inﬂammation and cytoprotection. In addition, engagement of
gp130 also leads to the activation of Ras-ERK1/2/MAPK and PI3K/
AKT pathways [7].
We have previously demonstrated that the parasite cysteine pro-
tease, cruzipain, when devoid of enzymatic activity, improves the
pro-survival effect elicited by the parasite in cardiomyocyte cultures
[8]. Related to this, cruzipain itself induces cardiomyocyte survival
through the activation of two signal transduction pathways, the
PI3K/Akt and MEK1/ERK, with both pathways leading to a decrease
in the activated caspase-3 [9]. However, the nature of the receptor
that interacts with cruzipain and subsequently triggers this molecular
mechanism still remains to be elucidated.
Cruzipain is the main T. cruzi papain-like cysteine protease and is
one of the most extensively studied parasite antigens. This enzyme
is expressed as a mixture of isoforms throughout all the developmen-
tal forms of the parasite and is constitutively secreted to the extracel-
lular milieu as free cruzipain and as cruzipain–chagasin complexes by
the trypomastigote infective stage. Its activity has been directly as-
sociated with intracellular amastigote survival [10,11], host cell in-
vasion [12–14] and induction of inﬂammation [15,16]. Reinforcing
previous results obtained in our laboratory [17,18], a more recent re-
port has suggested that cruzipain activity drives immune evasion
mechanisms by preventing macrophage classical activation [19]. Of
further interest, huge cruzipain deposits have been observed in the
cytoplasm of macrophages or free at the extracellular matrix during
human chronic chagasic myocarditis [20].
Herein, we investigated the putative effects of shed cruzipain on
cellular physiology, emphasizing its capacity to regulate IL-6 signaling
and cardioprotective effect. We found that cruzipain enzymatically
cleaved the IL-6 signal transducer gp130, and consequently abrogated
STAT3 phosphorylation, leading to the inhibition of IL-6-induced car-
dioprotection. This strategy may be critical during natural infection,
since the gp130 cleavage induced by the puriﬁed enzyme as well as
by trypomastigotes supernatants was independent of the cell type
analyzed.
2. Materials and methods
2.1. Animals
BALB/c and C57BL/6micewere purchased from Facultad de Ciencias
Veterinarias, UniversidadNacional de La Plata, Argentina. C57BL/10ScNJ
mice which were lacking the Tlr4 gene (Tlr4lps-del) and C57BL/6
TLR2-knockout (TLR2KO)micewere purchased from The Jackson Labo-
ratory, Bar Harbor, ME, USA. Animals were maintained at the Animal
Resource Facility of the CIBICI-CONICET (National Institutes of Health-USA assurance number A5802-01) following the recommendations in
the Guide for the Care and Use of Experimental Animals published by
the Canadian Council on Animal Care and approved by the CIBICI-
CONICET committee.
All animal experiments were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health, USA. The protocol was
approved by the Committee on the Ethics of Animal Experiments of
the Centro de Investigaciones en Bioquímica Clínica e Inmunología
(CIBICI)-CONICET.
2.2. Isolation of parasite molecules
Cruzipain was puriﬁed from Tulahuen epimastigotes, as described
by Giordanengo [17] followed by a fast protein liquid chromatography
(Amersham Pharmacia Biotech ÄKTAFPLC system) with a Superdex75
pre-packed column. For inactive cruzipain, the epimastigotes were
previously resuspended in sucrose solution containing the irrevers-
ible protease inhibitors TLCK and PMSF. For active cruzipain, the en-
zyme was pre-activated with 2.5 mM dithiothreitol (DTT) (Bio-Rad)
for 15 min at 37 °C immediately before being added to the cultures
since these enzymes need tomaintain the active-site cysteine in its re-
duced state to ensure activity. The Limulus amebocyte lysate assay
(Charles River Laboratories) was used to show that there was no en-
dotoxin presence. Recombinant chagasin was produced in E. coli and
puriﬁed as described by dos Reis et al. [21], and recombinant cruzipain
was obtained as described by Cazorla et al. [22].
2.3. T. cruzi supernatants
Trypomastigote forms (Tulahuen strain) obtained from the super-
natant of infected LLC-MK2 cells (a cell line from kidney adult Rhesus
monkey), were washed with HBSS, and 1×107 parasites/ml were
incubated in culture medium for 120 min at 37 °C. Then, parasites
were pelleted, and the conditioned media (CM) containing secreted
trypomastigote molecules were collected and ﬁltered. Aliquots of CM
were incubated with 2.5 mM DTT for 15 min at 37 °C to activate the
cysteine protease before use. Cultured cells were incubated with the
CM diluted 1:2 with culture medium and kept in a 5% CO2 incubator
at 37 °C. After 120 min, cells were treated with 10 ng/ml bioactive re-
combinant IL-6 (eBioscience) for an additional 15 min.
2.4. TLR ligand screening
TLR ligand screening was performed by Invivogen (Genbiotech
www.genbiotech.com.ar). Brieﬂy, TLR stimulation was tested in
HEK293 cells stably transfected with a plasmid that constitutively ex-
presses a given functional mouse TLR (TLR2, 3, 4, 5, 7, 8 and 9) and a
plasmid containing the SEAP reporter gene under the control of a pro-
moter inducible by NF-κB. Inactive cruzipain (5 μg/ml) was tested and
compared with the following control ligands: TLR2: HKLM (heat-killed
Listeria monocytogenes) (108 cells/ml), TLR3: Poly(I:C) (1 μg/ml),
TLR4: E. coli K12 LPS (1 μg/ml), TLR5: Salmonella typhimurium ﬂagel-
lin (1 μg/ml), TLR7: CL097 (1 μg/ml), TLR8: CL075 (1 μg/ml)+PolydT
(10 μM), and TLR9: CpG ODN 1826 (1 μg/ml). After 16–20 h incuba-
tion, the OD at 650 nm was read on an Absorbance Detector. Cells
transfected with control plasmid expressing the NF-κB inducible report-
er system stimulated with TNF-α (100 ng/ml) were used as control.
2.5. Primary cardiomyocyte cultures
Cardiomyocyte cultures from neonatal BALB/c, C57BL/6, C57BL/
10ScNJ (TLR4 deﬁcient) and C57BL/6 TLR2-knockout mice were carried
out as described previously [8]. The cultureswere kept in a 5% CO2 incu-
bator at 37 °C to allow the cells to start beating. More than 85% of cells
were found to be cardiomyocytes. After 24 h, the cells werewashed and
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active cruzipain (5 μg/ml), active cruzipain–chagasin complexes (1:1), re-
combinant cruzipain (5 μg/ml), bioactive recombinant IL-6 (10 ng/ml)
(eBioscience), LPS (1 μg/ml) (Invivogen), CM (Section 2.3), puriﬁed
rat anti-mouse IL-6 (5 μg/ml) (BD Pharmingen) or IgG1 isotype con-
trol (5 μg/ml) (BD Pharmingen). The cultures were maintained
in complete culture medium (10% FBS-DMEM) or in serum starved
conditions (0.1% FBS-DMEM). When indicated in the ﬁgure leg-
end, monolayers were pre-treated with the inhibitors: Ly294002
(25 mM) (Sigma-Aldrich), sulfasalazine (5 mM) (Sigma-Aldrich)
or PD098059 (38 mM) (Calbiochem) for 1 h and then incubated in
the medium containing the inhibitors in the presence or absence of in-
active cruzipain. The optimal inhibitor concentration was selected in
preliminary assays, based on their capacity to inhibit the kinase activity
andnot affect the cell survival rate. DMSOwas used as a vehicle at a con-
centration of 0.2%. Control cultures received the vehicle alone.
2.6. Spleen cell cultures
Splenic cell cultures were performed as described previously [17].
The spleens from BALB/c mice were mechanically disintegrated, red
blood cells were removed using lysis buffer (Sigma) and the remaining
cells were then plated at a density of 2.6×105 cells/cm2 in RPMI 1640
with gentamicin (both from Gibco). Cells were maintained in medium
alone or stimulated with inactive cruzipain (5 μg/ml), active cruzipain
(5 μg/ml) or active cruzipain–chagasin complexes (1:1). In another ex-
periment, cultured cells were incubated with CM pre-activated with
DTT (cruzipain activator) or without treatment. After 120 min of stim-
uli at 37 °C, cultures were treated with bioactive recombinant IL-6
(10 ng/ml) for 15 min.
2.7. Human peripheral blood mononuclear cell cultures
Peripheral blood was collected from healthy donors after obtaining
their signed informed consent. Themononuclear cells (PBMC)were iso-
lated on a Ficoll-Hypaque (GE Healthcare) density gradient by centrifu-
gation. Then the PMBCwere plated at a density of 2.6×105 cells/cm2 in
RPMI 1640 mediumwith gentamicin. Cultured cells were maintained in
mediumalone, or subjected to treatmentwith active cruzipain (5 μg/ml)
or recombinant cruzipain (5 μg/ml) for 120 min at 37 °C and then in-
cubated with 10 ng/ml of recombinant IL-6 for an additional 15 min.
The procedure for such collection and details of informed consents
were in accordancewith a proposal approved by the Institutional Ethics
Committee (Hospital Nuestra Señora de la Misericordia-Córdoba,
Argentina).
2.8. Cardiomyocyte transfection
Neonatal cardiac cell cultures from BALB/c mice were transfected
as was previously described [5]. After 2 days of culture, contracting
cardiomyocytes were transfected with dominant negative forms of
TLR2 (dn-TLR2) (pZERO-mTLR2) (0.5 μg/well) or the empty control
vector (pZERO-mcs) (0.5 μg/well) (both from Invivogen) using
Lipofectamine Plus Reagent (Invitrogen), following the manufacturer
protocol. Twenty-four hours after transfection, the cells were incubat-
ed with inactive cruzipain for 48 h. The supernatants were collected
for cytokine detection by ELISA and the transfection efﬁciency was
monitored by ﬂow cytometry (data not shown).
2.9. Measurement of apoptotic cell death
Following treatments for 48 h in serum starved conditions, the car-
diomyocyte monolayers were labeled with 5 μl of FITC-Annexin V (BD
Pharmingen) for 15 min on ice. Previous to the acquisition, the cells
were stained with propidium iodide. A minimum of 30,000 events for
each condition were analyzed by ﬂow cytometry (FACSCanto II, BectonDickinson), with cellular debris being excluded from the analysis. Data
were analyzed using FlowJo software.
2.10. Cytokine assays
The ELISA assay was performed for quantiﬁcation of cytokine levels.
Brieﬂy, ELISA plates were coated with anti-cytokine antibodies (BD
Pharmingen and e-Bioscience) overnight and thenwashed and blocked.
The culture supernatants obtained were incubated overnight, before
the plates were subjected to biotinylated anti-cytokine antibody (BD
Pharmingen and e-Bioscience) for 1 h. After washing, the plates were
incubatedwith streptavidin–peroxidase (BD Pharmingen). The reaction
was revealed using DakoCytomation TMB Substrate Chromogen
(Dako), before being read at 490 nm in a Microplate reader (Bio-Rad).
Standard curves were generated using recombinant cytokines (BD
Pharmingen and e-Bioscience).
2.11. Flow cytometric analysis
For the study of TLR2 and TLR4 expression, 2×105 cardiac cells
were stained with the following antibodies: PE-labeled monoclonal
anti-mouse TLR2 (eBioscience) or with Alexa Fluor 488-labeled
monoclonal anti-mouse TLR4 antibody (eBioscience). For detection
of gp130 (CD130) expression and D1 domain expression, stimulated
PBMC were harvested, ﬁxed and stained with the following anti-
bodies: mouse monoclonal anti-human gp130 (clone: B-T2, Abcam)
followed by PE-labeled monoclonal anti-mouse IgG1 (Biolegend), to-
gether with Alexa ﬂuor-647 conjugated polyclonal anti-human gp130
antibody (eBioscience) in concentrations recommended by the man-
ufacturer. Stained samples were acquired using the FACSCanto II
cytometer. Lymphocytes and monocytes were gated by FSC/SSC scat-
ter characteristics. Data were analyzed using FlowJo software.
2.12. Western blot assays
Cardiomyocyte or spleen cell cultures were subjected to different
stimuli for 120 min at 37 °C. Then, the cultureswere treatedwith bioac-
tive recombinant IL-6 (10 ng/ml) for 15 min and immediately har-
vested and mixed with loading buffer. Aliquots with equal amounts of
proteinwere separated on SDS-PAGE and electrotransferred to nitrocel-
lulose membranes (Bio-Rad Laboratories). After being blocked, the
membranes were incubated with rabbit polyclonal phospho-STAT3
antibody (Cell Signaling). Then, the membranes were incubated with
HRP-conjugated anti-rabbit antibody (Sigma) and assayed using the
ECL chemiluminescent system (Amersham Pharmacia Biotech). The
membranes were stripped and incubated with rabbit polyclonal anti-
STAT3 (Cell Signaling), washed and revealed. The band intensity for
p-STAT3 was semi-quantiﬁed by densitometric scanning and normal-
ized with respect to the total STAT3 using ImageJ processing software
(www.rsb.info.nih.gov/ij).
2.13. Colloidal silver staining procedure
Recombinant human gp130 (baculovirus-derived Leu24-Glu619,
Accession number # P40189, R&D Systems) was maintained in PBS
alone or incubated with active cruzipain at an enzyme/substrate
ratio of 1/100 (w/w) for 120 min at 37 °C. The reaction was stopped
by adding loading buffer to the mixture, and heated to 90 °C for
10 min. Samples were separated on SDS-PAGE and electrotransferred
to nitrocellulose membranes as described above. The protein silver
staining procedure was adapted from a technique published by
Kovarik et al. [23]. The membranes were washed in deionized water
and stained under gentle agitationwith a colloidal silver staining solu-
tion prepared immediately before use. The staining was stopped after
10 min by washing with running deionized water.
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To compare different experimental conditions, an analysis of vari-
ance (two-way or one-way ANOVA) with the Tukey post hoc test was
performed. A two-tailed Student' t-test was used for comparison
between control and experimental samples. A p-valueb0.05 was con-
sidered signiﬁcant with NS denoting non-signiﬁcant.
3. Results
3.1. Cruzipain triggers TLR2-signaling
We have recently demonstrated that T. cruzi protects isolated car-
diomyocytes from apoptosis through TLR2 triggering [5]. In addition,
we previously reported that treatment of cardiomyocytes with enzy-
matically inactive cruzipain resulted in an anti-apoptotic effect on
serum starved cultures [8].
In order to determine if inactive cruzipain was able to trigger TLR
signaling, a TLR ligand screening assay was performed. We found
that cruzipain had a selective stimulatory effect on TLR2-transfected
cells, as shown by the expression levels of SEAP in cruzipain-treated
cultures, which reached about 60% of the levels detected with the
TLR2 ligand HKLM (Fig. 1A). On the other hand, cruzipain did not pro-
mote any signiﬁcant activation of HEK293 cells transfected with other
TLR. Interestingly, cells transfected with control plasmid expressing
the NF-κB inducible reporter did not show NF-κB activation, either
constitutively or in response to cruzipain, although theywere strongly
stimulated by TNF-α treatment when used as a positive control
(Fig. 1A). Taken together, these results show that cruzipain by itself
was able to trigger TLR2, resulting in the activation of NF-κB.
3.2. TLR2 is involved in cardiomyocyte protection induced by cruzipain
In order to investigate the potential role of TLR2 in the cruzipain-
induced cytoprotective effect, cardiomyocyte primary cultures fromFig. 1. Cruzipain triggers the TLR2 pathway and consequently the survival of cultured cardi
gene and the NF-κB-inducible SEAP reporter gene (mTLRs) were left untreated (no ligand), a
trol +). The cells transfected with control plasmid expressing the NF-κB inducible reporter (
dent experiments carried out in duplicate with two different cruzipain samples. Cardiomy
treated with inactive cruzipain or untreated (control) and maintained in starved medium
in B, C and D are shown as mean±SEM of a representative assay of three independent expC57BL/6 or C57BL/6 TLR2KO were incubated with inactive cruzipain
for 48 h in serum starved conditions. In agreement with the results
obtained with cultured cardiomyocytes derived from BALB/c (Fig. 1B),
inactive cruzipain incubation decreased the percentage of apoptotic
cardiomyocytes derived from C57BL/6 mice (Fig. 1C), showing that
the survival effect was independent of the mouse strain. In contrast, in
cultures from TLR2KO mice, the anti-apoptotic effect induced by
cruzipain treatment was abrogated (Fig. 1D). These results strongly
suggest that the TLR2 triggering was critical for the cardiomyocyte sur-
vival induction in our model.
We next evaluated cell surface expression of TLR2 and TLR4 in cul-
tured cardiac myocytes at different time points post-stimuli with inac-
tive cruzipain, by ﬂow cytometry (Fig. 2). Cardiomyocytes were found
to express low constitutive levels of TLR2 and TLR4, andwhile cruzipain
treatment signiﬁcantly increased the percentage of TLR2-expressing
cells (Fig. 2A) and TLR2 surface expression (Fig. 2B), the rate of TLR4
positive cells was not signiﬁcantly altered during the culture period,
either in treated or untreated cultures (Fig. 2C). The up-regulation of
TLR2 involved PI3K and NF-κB-signaling pathways, but not MEK1 acti-
vation, since the pre-treatment with Ly294002 (PI3K inhibitor) or with
sulfasalazine (NF-κB inhibitor), but not with PD098059 (MEK1 inhibi-
tor), abrogated the increase in TLR2 (Fig. S1). In the absence of cruzipain,
the inhibitors had no effect on TLR2 expression (data not shown).
3.3. Inactivation of cruzipain is required to induce
cardiomyocyte survival
Considering that the previous assays were performed with
pharmacologically-inactivated cruzipain, we investigated whether
the enzymatic activity could interfere with its cardioprotective prop-
erties. To carry this out, Annexin V labeling was evaluated in cultures
treated with either active cruzipain or cruzipain devoid of enzymat-
ic activity through pharmacological treatment or complexed with
chagasin (Fig. 3). Surprisingly, we found that active cruzipain was un-
able to reduce the degree of serum deprivation-induced apoptosis inomyocytes. (A) HEK293 cells transfected with plasmids expressing a given mouse TLR
nd subjected to treatment with inactive cruzipain or with speciﬁc control ligands (con-
NF-κB control cells) were used as control. Data represent mean±SEM of two indepen-
ocyte monolayers from (B) BALB/c, (C) C57BL/6 and (D) C57BL/6 TLR2KO mice were
for 48 h. The apoptotic rate was evaluated by Annexin V-FITC labeling and FACS. Data
eriments performed in quadruplicate.
Fig. 2. Cruzipain increases the TLR2 expression on cardiomyocyte cultures. Primary cardiomyocyte cultures were treated with inactive cruzipain or maintained in medium alone
(control). The percentage (A) and the geometric mean of ﬂuorescence intensity (GMFI) for (B) TLR2 and (C) TLR4 expression were measured at 16 h and 24 h post-treatment.
The bars represent mean±SEM of three independent experiments performed in triplicate.
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chagasin restored its capability to promote cardioprotection (Fig. 3A).
To rule out the possible participation of TLR4 in the observed results,
we performed survival experiments with cardiomyocytes obtained
from C57BL/10ScNJ mice lacking the TLR4 gene (Fig. 3B). In agreement
with the results obtained with BALB/c cells, we found that inactive
cruzipain (pharmacologically-inactivated or complexed with chagasin)
signiﬁcantly reduced the apoptotic rate compared with cells main-
tained in medium alone or treated with active cruzipain (Fig. 3B). In
both models, chagasin alone did not show any effects on cell survival
(data not shown). Furthermore, as we described previously for infected
monolayers, pharmacologically-inactivated cruzipain or cruzipain-
chagasin treated cultures remained beating after 48 h of serum starva-
tion (Videos S2 and S4, respectively), in contrast to active cruzipain-
treated or untreated control cultures, which did not beat at this time
point (Videos S3 and S1, respectively).
3.4. Cruzipain stimulates the production of IL-6 through TLR2 and NF-κB
activation
We next sought to determine the cytokine proﬁle (IL-1β, TNF-α,
IL-12, IL-6, IL-17 and IL-10) produced as a consequence of cruzipain
stimulation in 16 h-culture supernatants. Among the cytokines test-
ed, only a rapid and sustained production of IL-6 in stimulated cul-
tures was detected (Fig. 4A), with IL-6 release being blocked by
pre-incubation with sulfasalazine. These ﬁndings illustrate that car-
diomyocyte cultures are able to respond to cruzipain efﬁciently by
producing IL-6 in a NF-κB activation-dependent manner. Depletion
of IL-6 by neutralizing antibodies in cruzipain-stimulated cultures
was found to abrogate the observed cytoprotection (Fig. S2).
To investigate if inactive cruzipain-induced IL-6 secretion oc-
curred as a result of TLR2 activation, cardiomyocytes were transfected
with a dominant-negative TLR2 plasmid (dnTLR2). In comparison
with untreated cells, signiﬁcant levels of IL-6 were found in stimulat-
ed cultures transfected with control vector. Nevertheless, the amountFig. 3. Inactivation of cruzipain is required for cardiomyocyte survival induction. (A) Ca
cruzipain, enzymatically active cruzipain, active cruzipain–chagasin complexes (active cruz
48 h. The apoptotic rate was measured and the data are shown as mean±SEM of a represeof IL-6 released by cells bearing the dnTLR2 construct after stimula-
tion dropped to levels similar to those secreted by unstimulated
monolayers (Fig. 4B). In agreement with this, there were no signiﬁ-
cant differences in the IL-6 levels produced upon cruzipain treatment
by cardiomyocytes derived from TLR2KO mice (Fig. 4D), in compari-
son with those produced by cultures derived from the C57BL/6 wild
type (Fig. 4C). These results show a direct correlation between the
activation of TLR2 and IL-6 production induced by inactive cruzipain.
Next, we tested the impact of cruzipain enzymatic activity on IL-6
production, and the ELISA data showed that the secretion of IL-6
was comparable in cultures subjected to inactive or active cruzipain
treatments (Fig. 4E).
3.5. Cruzipain activity prevents IL-6-induced STAT3 phosphorylation by
means of gp130 cleavage
Taking into account that IL-6 promotes anti-apoptosis through the
gp130 receptor predominantly via p-STAT3 [3,24], we next investigat-
ed if the cruzipain enzymatic activity interfered with gp130 signaling.
To carry this out, the degree of STAT3 phosphorylation was measured
in cardiomyocyte cultures pre-incubated for 120 min with inactive or
active cruzipain before they were stimulated with recombinant IL-6,
and it was found that enzymatically active cruzipain, but not the inac-
tive one, completely abrogated the STAT3 phosphorylation and nucle-
ar translocation induced by IL-6 (Figs. 5A and S3).
As the signaling pathway IL-6/gp130/STAT3 is crucial in several
immune cell compartments during the inﬂammatory response, we
evaluated if the activity of cruzipain could interfere with IL-6 signaling
in murine spleen cells. In fact, pre-incubation with active cruzipain
signiﬁcantly diminished the p-STAT3 expression induced by IL-6, but
the inhibition was reverted when the enzyme was complexed with
chagasin (Fig. 5B). Next, considering that cruzipain is released by
trypomastigotes during natural infection [12], spleen cells were pre-
incubated with CM treated with DTT (cruzipain activator) or without
treatment, and then subjected to IL-6 stimulation (Fig. 5C). Therdiomyocytes from BALB/c or (B) TLR4-deﬁcient mice were incubated with inactive
ipain+chagasin) or were untreated (control) and maintained in starved medium for
ntative assay of three independent experiments performed in quadruplicate.
Fig. 4. Cruzipain induces the production of IL-6 by cardiomyocyte cultures. The cytokine production was quantiﬁed by ELISA in supernatants collected from the following cultures:
(A) BALB/c primary cardiomyocyte cultures were left untreated (control) or incubated with inactive cruzipain for 16 h. Some monolayers were pre-incubated with sulfasalazine.
(B) Transiently transfected cardiac myocytes with dnTLR2 or the empty control vector were incubated with inactive cruzipain for 48 h. (C) Cultures obtained from C57BL/6 or
(D) TLR2KO mice were incubated with inactive cruzipain or LPS for 16 h. (E) Cultures from BALB/c mice were stimulated with inactive or active cruzipain for 48 h. The results
are expressed as mean±SEM of at least four independent experiments performed in triplicate.
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CM obtained from non-treated trypomastigotes partially allowed IL-6
signaling. Furthermore, spleen cells incubated with trypomastigotes
(cell:parasite ratio 1:3) also permitted the fully STAT3 phospho-
rylation (Fig. 5C). In agreement, we found that starved cardiac cell
cultures-treated with CM were rescued against apoptosis, while the
supernatants activatedwith DTT partially lost the anti-apoptotic prop-
erties (Fig. 5D).
To determine if gp130 was substrate of cruzipain, we analyzed the
expression of gp130 N-terminal domain (D1) on human PBMC sub-
jected to cruzipain activity. To address this issue, it was employed the
B-T2 mAb, which recognize an epitope on Ig-like domain (D1) of
human gp130. The treatment resulted in a signiﬁcant decrease in the
amount of the D1 expression on lymphocytic (Fig. 6A) and monocytic
populations (Fig. 7A). In contrast, the gp130 global expression, evaluat-
ed through the reactivity of a polyclonal antibody, remained unaltered
(Figs. 6B and 7B, respectively). Comparable results were also obtained
with pre-activated recombinant cruzipain (Fig. S4). To characterize fur-
ther the gp130 cleavage resulting from cruzipain activity, the recombi-
nant human gp130 ectodomain was incubated with active cruzipain,
and the products released were run on SDS-PAGE and electrotrans-
ferred to nitrocellulose. In contrast to the untreated peptide that
appeared as a single band corresponding to a 68 kDamolecular weight,
the cruzipain-treated recombinant gp130 showed three additional
bands with lower molecular weights (Fig. 8). These ﬁndings clearly
demonstrate that cruzipain was able to cleave the human gp130 extra-
cellular domain.4. Discussion
Cruzipain is one of the T. cruzi molecules that have received the
most attention by the scientiﬁc community. This parasite depends
on its cysteine protease activity to invade and develop inside target
mammalian host cells. Therefore, due to its crucial importance for
parasite survival, inhibitors of cruzipain activity are attractive candi-
dates for the therapeutic treatment of Chagas disease. The current
study provides the ﬁrst evidence that the parasite may manage the
IL-6-induced response by means of gp130 cleavage, through the mod-
ulation of its cysteine protease activity.
We recently reported that T. cruzi induces cardioprotection through
the activation of TLR2 and the subsequent secretion of IL-6 [5]. IL-6 re-
leased in response to parasite infection is able to induce STAT3 phosphor-
ylation in cultured cardiomyocytes, a well-recognized mediator of cell
survival [24]. Here, it is demonstrated that puriﬁed pharmacologically-
inactivated cruzipain induced a strong TLR2 expression on cardio-
myocytes. These results support our earlier observations in which the
anti-apoptotic effect elicited by T. cruzi was signiﬁcantly enhanced by
pre-incubation with cruzipain [8]. We also demonstrated that inactive
cruzipainwas able to speciﬁcally trigger TLR2 signaling andNF-κB activa-
tion to promote IL-6 secretion. Thereby, the TLR2/NF-κB/IL-6 pathway
may be critical in the previously reported cruzipain-cardioprotective ef-
fect [9].
Considering that the trans-sialidase (another T. cruzi enzyme) is
able to induce the protection of Schwann cells from apoptosis [25] in
a manner independent of its enzymatic activity, we investigated the
Fig. 5. Cysteine protease enzymatic activity abrogates STAT3 phosphorylation in different cell types. (A and D) BALB/c cardiomyocyte cultures and (B and C) spleen cell cultures,
when indicated, were treated with inactive cruzipain, active cruzipain, active cruzipain–chagasin complexes (active cruzipain+chagasin), CM pre-treated with DTT (CM+DTT),
untreated CM or with trypomastigotes (T. cruzi). (A, B and C) After 120 min, the cells were stimulated with recombinant IL-6 for 15 min. The STAT3 phosphorylation was estimated
by immunoblotting with anti-p-STAT3 or anti-STAT3 antibodies. The band intensity for p-STAT3 was normalized with respect to the total STAT3. (D) After 48 h of starvation, the
apoptotic rate of cardiomyocyte was evaluated by Annexin V-FITC labeling and FACS. The results are shown as mean±SEM of at least three independent experiments.
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active cruzipain was unable to evoke signiﬁcant cardiomyocyte pro-
tection against apoptosis, although this property was restored when
the enzyme was complexed with its natural inhibitor chagasin. This
different anti-apoptotic response was observed despite the fact that
both stocks of cruzipain induced comparable levels of IL-6. We there-
fore hypothesize that cruzipainmay promote downstream IL-6 signal-
ing blockage by means of its enzymatic activity. Indeed, the pre-
treatment of cardiac cell monolayers with active cruzipain completely
abrogated the phosphorylation and nuclear translocation of STAT3 in-
duced by IL-6, thereby providing evidence that these cells became
unresponsive to IL-6 stimulation. Moreover, CM obtained from trypo-
mastigotes prevent apoptosis of starved cardiac cells but this effect
was only partially reverted when the supernatants were activated
with DTT, strongly suggesting that inactive enzyme stock released at
the infective stage of the parasite is likely responsible for the rescue
against apoptosis. Nevertheless, the cytoprotection was inversely cor-
relatedwith the cysteine protease activity since the survival effect was
not observed in a reducing environment, which ensures the catalytic
activity of free cruzipain through the maintenance of the active-site
cysteine in its reducing state.
The role of cruzipain with enzymatic activity has been widely doc-
umented through in vitro [12,13,26] and in vivo cellular systems [27],
using DTT as a reducing agent to ensure cruzipain activity. Neverthe-
less, its effect without activity has not been thoroughly investigated.
The T. cruzi secretes signiﬁcant amounts of free cruzipain, as well as
of cruzipain complexed with chagasin [11], which could therefore
provide the source of inactive cruzipain that is capable of promotingcytoprotection. Alternatively, cruzipain inactivated through interac-
tions with mammalian inhibitors, such as the alfa 2-macroglobulin
present in host plasma [28], may also mediate the anti-apoptosis dur-
ing natural infection. In this sense, huge cruzipain deposits have been
observed in the extracellular matrix of heart tissue during human
chronic chagasic myocarditis [20]. Moreover, although in the myocar-
dium of chagasic patients, apoptotic cells is found in high number, no
apoptotic cardiomyocytes are detected and the majority of TUNEL-
positive cells havemacrophage markers [29]. In the light of the results
described here, it is plausible to speculate that cruzipain remains in
the myocardium under its inactive form, stimulating the cardiac cell
survival in an unfavorable environment.
We were not able to determine whether inactive cruzipain pro-
motes TLR2 activation directly by acting as a TLR2 ligand or by exerting
its effect indirectly through interactionwith additional cell surfacemol-
ecules. Nevertheless, our results showed strong correlations among
cruzipain and TLR2 activation, IL-6 production and cardioprotection,
which suggest there are potential unforeseen roles for cruzipain-
chagasin complexes. In line with this observation, in vivo kinetic study
has revealed us that infected IL-6KO mice, rather than TLR2KO mice,
showed signiﬁcantly more TUNEL-positive cardiac cells than infected
wild type mice (unpublished data).
The gp130-mediated STAT3 signals are involved in multiple steps of
the immune response. Here, we also demonstrated that the blockade of
gp130 downstream signaling was irrespective of the cell type analyzed.
In fact, active cruzipain abrogated the IL-6-induced STAT3 phosphor-
ylation in murine spleen cells, with this inhibition being mediated
by its enzymatic activity, since it was reversed when cruzipain was
Fig. 6. Cruzipain activity reduces the gp130 D1 domain expression on human peripheral blood lymphocytes. Mononuclear cells were incubated with active cruzipain for 120 min.
Then, the expression (percentage of positive cells and GMFI) of (A) gp130 D1 Domain and (B) global gp130 was determined on lymphocytes by ﬂow cytometry. Peripheral blood
lymphocyte subsets were gated by FSC/SSC scatter properties. Representative histograms (right) of D1 domain and gp130 expression on treated or untreated (control) cells are
shown. The data (mean±SEM) are representative of two independent experiments performed in quadruplicate.
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DTT-activated CMexerted the same effect as active cruzipain. Neverthe-
less, when the splenocytes were incubated with non-treated CM, the
IL-6-induced p-STAT3 expression was diminished but not completelyFig. 7. Cruzipain activity diminishes the gp130 D1 domain expression on human peripheral
Then, the expression (percentage of positive cells and GMFI) of (A) gp130 D1 domain and
monocyte subsets were gated by FSC/SSC scatter properties. Representative histograms (r
shown. The data (mean±SEM) are representative of two independent experiments perforabrogated, suggesting that part of the soluble factor(s) released by the
parasite itself was activated but coexisted with inactive stock of the en-
zyme. Under our experimental conditions, active infection with live
parasites did not reduce the expression of p-STAT3 induced by IL-6.blood monocytes. Mononuclear cells were incubated with active cruzipain for 120 min.
(B) global gp130 was determined on monocytes by ﬂow cytometry. Peripheral blood
ight) of D1 domain and gp130 expression on treated or untreated (control) cells are
med in quadruplicate.
Fig. 8. Recombinant human gp130 is cleaved by cruzipain enzymatic activity. Recombi-
nant gp130 ectodomain was incubated with active cruzipain for 120 min at 37 °C (lane
2) ormaintained in PBS (lane 1). Sampleswere separated on SDS-PAGE, electrotransferred
to the nitrocellulose membrane and the proteins were evidenced by silver staining.
Cruzipain, at the concentration employed in the experiment, was run on lane 3.
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the parasites continuously release cysteine proteaseswhich act in a sys-
temic way by diffusing in the entire host's organism thus modulating
the pleiotropic IL-6 downstream signaling. Since, in addition to IL-6,
a large number of cytokines can signal through gp130 (IL-11, IL-27,
leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor,
cardiotrophin-1 and cardiotrophin-like cytokine), a decrease in the
gp130-mediated signalingmay have a broad impact on a number of im-
munological mechanisms.
The cytokine receptor gp130 requires the Ig-like domain (D1) in
order to be functionally responsive to IL-6 cytokine [30,31]. It has
been previously reported that DTT-activated cruzipain enzymatically
cleaves the hinge regions of all human IgG subclasses [26]. Further-
more, considering that the B-T2 monoclonal antibody speciﬁcally rec-
ognizes the epitope in the D1 domain of human gp130, we performed
a ﬂow cytometry analysis of the expression of this domain on human
peripheral blood mononuclear cells pre-treated with active cruzipain.
Although the global expression of gp130 remained unaltered, the ac-
tive enzyme induced a reduction in the D1 domain expression in dif-
ferent degrees of signiﬁcance in the analyzed leukocyte subsets. This
native cruzipain catalytic effect was reproduced by pre-activated re-
combinant cruzipain, thus demonstrating that the observed effect
was speciﬁc to cruzipain. As was expected, the treatment with the in-
active form of enzyme did not modify the D1 domain expression (data
not shown). These data strongly suggest that the cruzipain enzymatic
activity essentially involves the release of the Ig-like domain region on
human gp130. Reinforcing these results, the recombinant human
gp130 ectodomain was cleaved by the action of cruzipain. Taking
into account that glycosylation protects protein against proteolytic
degradation; it is plausible to think that under native conditions the
gp130 extracellular domain on host cells underwent a lower digestion
than the one observed in the gel. The identiﬁcation of the amino acid
sequences at the gp130 cleavage site is an aim of future investigations
in our laboratory.
Interleukin-6 is a potent, pleiotropic, inﬂammatory cytokine that
mediates a plethora of physiological functions, including cell prolifer-
ation, cell survival and amelioration of apoptotic signals. Depending
upon the cell type, IL-6 is able to act through several classic protein
kinase cascades such as MAPKs and PI-3 kinase. Administration of
IL-6 induces the up-regulation of TLR2 mRNA but it does not affect
the TLR4 mRNA levels on hepatocytes [32]. In agreement, in our
model we found that cruzipain induced IL-6 secretion and the strong
up-regulation of TLR2 but not of TLR4 surface expression. The increase
in TLR2 positive population was dependent on NF-κB and PI3K/Akt,but independent of the MEK1/ERK signaling pathways. Moreover,
cardiomyocytes stimulated with active cruzipain as well as IL-6 also
increased the TLR2 expression (data not shown). Therefore, it is possi-
ble to speculate that IL-6 increased the TLR2 expressing cells through
the activation of the PI3K/Akt/NF-κB signaling pathway. In this regard,
it is important to stress that T. cruzi induces the expression of TLR2 in
cardiac cells in the myocardium during experimental acute infection.
5. Conclusion
Our data suggest that the main parasite cysteine protease, devoid of
enzymatic activity, triggers TLR2 up-regulation and signaling, leading to
the subsequent release of pleiotropic IL-6. In this way, the parasite de-
velops strategies that confer cardiomyocyte protection in response to
such inﬂammatory environments. However, T. cruzimay modulate the
enzymatic activity of the released proteases in order to maintain a
stock of catalytically active cruzipain, which is capable of cleaving the
cytokine receptor gp130. Considering that the signaling through
gp130 by IL-6 family cytokines is involved in multiple steps of the im-
munological response, this might be a central mechanism for T. cruzi
immune evasion.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.12.003.
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